USFDA issues ‘zero’ 483 observations for Hikal’s Bengaluru plant

10/01/2017 15:25

Hikal Ltd said that the US healthy regulator has issued ‘’zero” 483 observations for the company’s facility located at Bangalore.

The pharmaceutical company said that its active pharmaceutical ingredient (API) and intermediates manufacturing facility located at Jigani, Bangalore was recently inspected by the United State Food and Drug Administration (US FDA) in compliance with their requirements.

“At the end of the successful inspection, we have been informed by the Investigator that “zero” 483 observations were issued. This was a routine inspection by the US FDA”, Hikal said in a regulatory filing.

Meanwhile, shares of the company closed trading at Rs 247 apiece, up 13.33 per cent from the previous close on BSE.


Leave a Reply

Fill in your details below or click an icon to log in: Logo

You are commenting using your account. Log Out /  Change )

Google+ photo

You are commenting using your Google+ account. Log Out /  Change )

Twitter picture

You are commenting using your Twitter account. Log Out /  Change )

Facebook photo

You are commenting using your Facebook account. Log Out /  Change )


Connecting to %s